Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/eje.0.1330675
European Journal of Endocrinology, Vol 133, Issue 6, 675-677
Copyright © 1995 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sassolas, G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Sassolas, G.

Medical therapy with somatostatin analogues for acromegaly

Geneviève Sassolas

The isolation, characterization and subsequent synthesis of a somatotropin-releasing factor (SRIH) in 1973 was logically and promptly followed by the demonstration of its application in clinical studies in acromegalic patients (1). Inhibition of growth hormone (GH) secretion was obtained by continuous intravenous infusion of the native peptide, which unfortunately has an ultra-short biological half-life. Despite the attraction for endocrinologists of a therapy that acts specifically at the cellular level, in contrast to the relative crudeness of ablative therapy for pituitary adenomas, this potential treatment remained undeveloped for another 10 years. Further progress had to wait until analogues with enhanced stability and higher specificity for GH inhibition became available. The considerable success of this "new treatment for an old disease" (2) is reflected by the number of papers (more than 35) published between 1985 and 1992, reporting the effects of treatment with somatostatin analogues (3–6). A new era was opened with




This article has been cited by other articles:


Home page
Endocr. Rev.Home page
S. L. S. Drop, W. J. de Waal, and S. M. P. F. de Muinck Keizer-Schrama
Sex Steroid Treatment of Constitutionally Tall Stature
Endocr. Rev., October 1, 1998; 19(5): 540 - 558.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Melmed, I. Jackson, D. Kleinberg, and A. Klibanski
Current Treatment Guidelines for Acromegaly
J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2646 - 2652.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 European Society of Endocrinology.